【券商聚焦】东北证券维持医渡科技(02158)“增持”评级 指其AI医疗平台业务覆盖持续扩张

金吾财讯
Aug 01

金吾财讯 | 东北证券研报指,医渡科技(02158)近期发布2025财年财报,本报告期内,公司实现总营业收入7.15亿元(-11.4%);税前利润为-1.35亿元(亏损同比减少39%);实现归母净利润-1.18亿元(亏损同比减少39.6%)。该机构指,公司营收略有下滑主要系外部市场环境及产品组合变化所致。此外,AI医疗平台业务覆盖持续扩张,收入结构优化。截至2025年3月31日,公司大数据平台已服务110家中国顶级医院及44个监管机构,覆盖超过4,000家医院。平台活跃用户数超过24百万名,且用户已完成至少一笔交易,显示出强大的用户触达能力和健康管理服务的市场接受度,为未来商业化变现奠定坚实基础。

该机构预计公司2026-2028财年收入8.22/9.82/11.83亿,归母净利润-0.62/-0.36/1.25亿,每股收益为-0.06/0.03/0.12元/股,维持“增持”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10